124 related articles for article (PubMed ID: 1906863)
21. Pharmacodynamics of once- versus twice-daily dosing of nebulized amikacin in an in vitro Hollow-Fiber Infection Model against 3 clinical isolates of Pseudomonas aeruginosa.
Heffernan AJ; Sime FB; Naicker S; Andrews K; Ellwood D; Guerra-Valero Y; Wallis S; Lipman J; Grimwood K; Roberts JA
Diagn Microbiol Infect Dis; 2021 Jun; 100(2):115329. PubMed ID: 33714790
[TBL] [Abstract][Full Text] [Related]
22. Postantibiotic effects of gentamicin and netilmicin on Serratia marcescens: effects on hydrophobicity and motility.
Majtánová L; Majtán V
Folia Microbiol (Praha); 2000; 45(1):45-9. PubMed ID: 11200671
[TBL] [Abstract][Full Text] [Related]
23. Nonspecific aminoglycoside cross-resistance of Serratia marcescens.
Traub WH; Fukushima PI
Chemotherapy; 1979; 25(4):204-13. PubMed ID: 378576
[TBL] [Abstract][Full Text] [Related]
24. Post-antibiotic effect of isepamicin compared to that of other aminoglycosides.
Minguez F; Agra M; Lurueña S; Ramos C; Prieto J
Drugs Exp Clin Res; 1990; 16(5):231-5. PubMed ID: 2078989
[TBL] [Abstract][Full Text] [Related]
25. Antibacterial activity of achievable epithelial lining fluid exposures of Amikacin Inhale with or without meropenem.
So W; Crandon JL; Hamada Y; Nicolau DP
J Antimicrob Chemother; 2016 Feb; 71(2):428-37. PubMed ID: 26559690
[TBL] [Abstract][Full Text] [Related]
26. [In vitro interaction of piperacillin and imipenem/cilastatin combined with aminoglycosides against Pseudomonas aeruginosa].
Yamashiro Y; Ogake N; Takahata M; Minami S
Jpn J Antibiot; 2000 Apr; 53(4):194-200. PubMed ID: 10868299
[TBL] [Abstract][Full Text] [Related]
27. Determination of optimal dosage regimen for amikacin in healthy volunteers by study of pharmacokinetics and bactericidal activity.
Garraffo R; Drugeon HB; Dellamonica P; Bernard E; Lapalus P
Antimicrob Agents Chemother; 1990 Apr; 34(4):614-21. PubMed ID: 2111658
[TBL] [Abstract][Full Text] [Related]
28. Serum bactericidal activity and postantibiotic effect in serum of patients with urinary tract infection receiving high-dose amikacin.
Van der Auwera P; Klastersky J
Antimicrob Agents Chemother; 1987 Jul; 31(7):1061-8. PubMed ID: 3116918
[TBL] [Abstract][Full Text] [Related]
29. Use of in vitro critical inhibitory concentration, a novel approach to predict in vivo synergistic bactericidal effect of combined amikacin and piperacillin against Pseudomonas aeruginosa in a systemic rat infection model.
Chan E; Zhou S; Srikumar S; Duan W
Pharm Res; 2006 Apr; 23(4):729-41. PubMed ID: 16554956
[TBL] [Abstract][Full Text] [Related]
30. Amikacin, ceftazidime, and flucloxacillin against suspended and adherent Pseudomonas aeruginosa and Staphylococcus epidermidis in an in vitro model of infection.
Vergères P; Blaser J
J Infect Dis; 1992 Feb; 165(2):281-9. PubMed ID: 1730894
[TBL] [Abstract][Full Text] [Related]
31. [Comparative activity of habekacin and 4 other aminoglycosides against gram-negative bacilli. Evolution of resistance].
Reynaud AE; Coude du Foresto B; Derriennic M; Courtieu AL
Pathol Biol (Paris); 1988 May; 36(5):435-8. PubMed ID: 3136424
[TBL] [Abstract][Full Text] [Related]
32. Once-versus thrice-daily netilmicin combined with amoxicillin, penicillin, or vancomycin against Enterococcus faecalis in a pharmacodynamic in vitro model.
Schwank S; Blaser J
Antimicrob Agents Chemother; 1996 Oct; 40(10):2258-61. PubMed ID: 8891125
[TBL] [Abstract][Full Text] [Related]
33. Synergic post-antibiotic effect of amikacin in combination with beta-lactam antibiotics on gram-negative bacteria.
Isaksson B; Hanberger H; Maller R; Nilsson LE; Nilsson M
J Antimicrob Chemother; 1991 Jul; 28(1):25-34. PubMed ID: 1769941
[TBL] [Abstract][Full Text] [Related]
34. In vitro activity of netilmicin, gentamicin, tobramycin and amikacin against glucose fermenting and nonfermenting bacteria.
DiPersio JR; Krafczyk TL
Chemotherapy; 1980; 26(5):323-33. PubMed ID: 7389428
[TBL] [Abstract][Full Text] [Related]
35. [Sensitivity of Pseudomonas aeruginosa to amikacin and to isepamicin in surgery and in intensive care].
Vincent P; Vachée A; Izard D
Pathol Biol (Paris); 1997 Nov; 45(9):771-5. PubMed ID: 9538477
[TBL] [Abstract][Full Text] [Related]
36. Postantibiotic effect in Pseudomonas aeruginosa following single and multiple aminoglycoside exposures in vitro.
Karlowsky JA; Zhanel GG; Davidson RJ; Hoban DJ
J Antimicrob Chemother; 1994 May; 33(5):937-47. PubMed ID: 8089067
[TBL] [Abstract][Full Text] [Related]
37. Comparison of gentamicin dosing regimens using an in-vitro model.
Begg EJ; Peddie BA; Chambers ST; Boswell DR
J Antimicrob Chemother; 1992 Apr; 29(4):427-33. PubMed ID: 1607331
[TBL] [Abstract][Full Text] [Related]
38. Impact of netilmicin regimens on the activities of ceftazidime-netilmicin combinations against Pseudomonas aeruginosa in an in vitro pharmacokinetic model.
Blaser J; Stone BB; Groner MC; Zinner SH
Antimicrob Agents Chemother; 1985 Jul; 28(1):64-8. PubMed ID: 3929682
[TBL] [Abstract][Full Text] [Related]
39. Changes in serum sensitivity and hydrophobicity in a clinical isolate of Klebsiella pneumoniae treated with subinhibitory concentrations of aminoglycosides.
Hostacká A
Zentralbl Bakteriol; 1998 Dec; 288(4):519-26. PubMed ID: 9987190
[TBL] [Abstract][Full Text] [Related]
40. Update on good use of injectable aminoglycosides, gentamycin, tobramycin, netilmycin, amikacin. Pharmacological properties, indications, dosage, and mode of administration, treatment monitoring.
Agence française de sécurité sanitaire des produits de santé
Med Mal Infect; 2012 Jul; 42(7):301-8. PubMed ID: 22770656
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
